Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Oct 29, 2024 (filed on Oct 30, 2024)Insider Name:Allgeier Christina LOwnership Type:Direct OwnershipSecurities:SSKN Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Jul 15, 2024 (filed on Jul 17, 2024)Insider Name:Geiger UriOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:230,573Price:$3.14
-
Jul 15, 2024 (filed on Jul 17, 2024)Insider Name:Accelmed Partners, L.P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:230,573Price:$3.14
-
Jul 15, 2024 (filed on Jul 17, 2024)Insider Name:Rafaeli DolevOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:19,100Price:$3.14
Filings by filing date
-
Oct 29, 2024 (filed on Oct 30, 2024)Insider Name:Allgeier Christina LOwnership Type:Direct OwnershipSecurities:SSKN Stock OptionsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20,000Price:--
-
Jul 15, 2024 (filed on Jul 17, 2024)Insider Name:Geiger UriOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:230,573Price:$3.14
-
Jul 15, 2024 (filed on Jul 17, 2024)Insider Name:Accelmed Partners, L.P.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:230,573Price:$3.14
-
Jul 15, 2024 (filed on Jul 17, 2024)Insider Name:Rafaeli DolevOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:19,100Price:$3.14
News
Biz Brief
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 5 Walnut Grove Dr Ste 140 HORSHAM PA 19044-2252 |
| Tel: | 1-404-7363 |
| Website: | www.strataskinsciences.com |
| IR: | See website |
| Key People | ||
| Uri Geiger Independent Chairman of the Board | Dolev Rafaeli President, Chief Executive Officer, Vice Chairman of the Board | John Gillings Principal Financial Officer, Principal Accounting Officer | Shmuel Gov Chief Operating Officer |
| Business Overview |
| STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company's products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC. |
| Financial Overview |
| For the nine months ended 30 September 2024, STRATA Skin Sciences Inc revenues decreased 3% to $24M. Net loss decreased 21% to $5.6M. Revenues reflect Dermatology Recurring Procedures segment remaining flat at $10.7M, United States (Country) segment decrease of 8% to $11M. Lower net loss reflects Dermatology Recurring Procedures segment income increase from $453K to $1.6M. |
| Employees: | 99 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $20.40M as of Sep 30, 2024 |
| Annual revenue (TTM): | $32.68M as of Sep 30, 2024 |
| EBITDA (TTM): | -$0.93M as of Sep 30, 2024 |
| Net annual income (TTM): | -$9.38M as of Sep 30, 2024 |
| Free cash flow (TTM): | -$1.99M as of Sep 30, 2024 |
| Net Debt Last Fiscal Year: | $8.09M as of Sep 30, 2024 |
| Shares outstanding: | 4,171,161 as of Sep 30, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |